SELECTED FINANCIAL STATEMENT INFORMATION (Tables)

9 Months Ended

Jul. 31, 2017

Selected Financial Statement Information [Abstract]

Schedule of Accounts Receivable [Table Text Block]

Accounts Receivable

(in thousands)	July 31, 2017			October 31, 2016
Accounts receivable		$209,873			$205,386
Less: Allowance for doubtful accounts	(3,468		)	(3,159		)
Accounts receivable, net		$206,405			$202,227

Schedule of Costs in Excess of Billings and Billings in Excess of Costs [Table Text Block]

Costs and Estimated Earnings on Uncompleted Percentage-of-Completion Contracts

(in thousands)	July 31, 2017			October 31, 2016
Costs incurred on uncompleted contracts		$24,114			$19,086
Estimated earnings	17,463			13,887
	41,577			32,973
Less: Billings to date	(43,652		)	(39,142		)
		($2,075	)		($6,169	)
Included in the accompanying Condensed Consolidated Balance Sheets under the following captions:
Accounts receivable, net (costs and estimated earnings in excess of billings)		$3,730			$4,839
Accrued expenses and other current liabilities (billings in excess of costs and estimated earnings)	(5,805		)	(11,008		)
		($2,075	)		($6,169	)

Schedule of Inventories [Table Text Block]

Inventories

(in thousands)	July 31, 2017			October 31, 2016
Finished products		$171,587			$131,008
Work in process	39,893			36,076
Materials, parts, assemblies and supplies	126,246			117,153
Contracts in process	3,536			3,253
Less: Billings to date	(791		)	(1,188		)
Inventories, net of valuation reserves		$340,471			$286,302

Schedule of Property, Plant and Equipment [Table Text Block]

Property, Plant and Equipment

(in thousands)	July 31, 2017			October 31, 2016
Land		$5,099			$5,090
Buildings and improvements	86,592			79,205
Machinery, equipment and tooling	189,577			171,717
Construction in progress	9,887			10,453
	291,155			266,465
Less: Accumulated depreciation and amortization	(161,250		)	(144,854		)
Property, plant and equipment, net		$129,905			$121,611

Schedule of Research and Development Expenses [Table Text Block]

The amount of new product research and development ("R&D") expenses included in cost of sales for the nine and three months ended July 31, 2017 and 2016 is as follows (in thousands):

	Nine months ended July 31,				Three months ended July 31,
	2017		2016		2017		2016
R&D expenses		$33,889		$32,666		$11,420		$12,674

Schedule of Redeemable Noncontrolling Interests [Table Text Block]

Management's estimate of the aggregate Redemption Amount of all Put Rights that the Company could be required to pay is as follows (in thousands):

	July 31, 2017		October 31, 2016
Redeemable at fair value		$83,244		$85,574
Redeemable based on a multiple of future earnings	43,637		13,938
Redeemable noncontrolling interests		$126,881		$99,512

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

Changes in the components of accumulated other comprehensive loss for the nine months ended July 31, 2017 are as follows (in thousands):

	Foreign Currency Translation			Pension Benefit Obligation			Accumulated Other Comprehensive Loss
Balances as of October 31, 2016		($23,953	)		($1,373	)		($25,326	)
Unrealized gain	16,737			—			16,737
Amortization of unrealized loss on defined benefit pension plan, net of tax	—			22			22
Balances as of July 31, 2017		($7,216	)		($1,351	)		($8,567	)